USPTO serial 76720853
BIOTEST
Reviewed by CopyMark Law Group
Status 807Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- HUSSAIN, TASNEEM
- Law office
- TMO LAW OFFICE 118
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with BIOTEST?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John W. McGlynn
John W. McGlynn Buchanan Ingersoll & Rooney, P.C.2200 Renaissance BoulevardSuite 350King of Prussia, PA 19406Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological preparations for use in industry and science, namely, proteins and protein preparations made from human blood, blood plasma or blood serum, in particular human albumin, coagulation factors and immunoglobulins; plasma fractions in the nature of biological preparations for industrial and scientific use; excipients for the stabilization of medicines, in particular human albumin for industrial and scientific purposes | ACTIVE | — |
| 005 | Pharmaceutical preparations for treating infectious diseases and diseases of the immune system, namely, proteins and protein preparations made from human blood, blood plasma or blood serum; pharmaceutical preparations for the treatment or prevention of blood or bleeding disorders, namely, coagulation factors and coagulation inhibitors, in particular fibrinogen; pharmaceutical preparations for the treatment or prevention of blood disorders, namely, immunoglobulin preparations, immunoglobulins; pharmaceutical preparations for the treatment or prevention of blood or bleeding disorders, namely, coagulation factors; pharmaceutical preparations for haematology, immunology, neurology, intensive medicine, transplantation medicine, oncology for the prevention and treatment of immune system-related diseases and disorders, neurological diseases and disorders, and infections; pharmaceutical preparations for preventing and treating viral diseases, for treating diseases of the immune system, for treating autoimmune diseases and oncological diseases; immunosuppressant, immunomodulatory, anti-inflammatory, antiallergic, hyposensitizing and detoxifying and toxin-neutralizing medicines | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BIOTEST GMBH & CO. KGAA
- Other trademarks owned by Biotest AG
- Other trademarks owned by Biotest AG
- Other trademarks owned by BIOTEST GMBH & CO. KGAA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Similar marks named BIOTEST
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Oct 28, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 28, 2026 | CNRT | SU - NON-FINAL ACTION - WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 26, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 23, 2026 | IUAF | USE AMENDMENT FILED | — |
| Oct 23, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Aug 15, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 14, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Aug 7, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 23, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 22, 2026 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 15, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 4, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Sep 4, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Sep 4, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 5, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 4, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Apr 4, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Apr 4, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 7, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 7, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Oct 7, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Oct 7, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 25, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 25, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 15, 2024 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Aug 15, 2024 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Aug 15, 2024 | PETG | PETITION TO REVIVE-GRANTED | — |
| Aug 15, 2024 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jul 12, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 27, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 24, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 24, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Aug 29, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 29, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 9, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 24, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 13, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 13, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 13, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 13, 2023 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 13, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 10, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 28, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 24, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 22, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 22, 2022 | TRPT | REQUEST FOR TRANSFORMATION PROCESSED - TOTAL | — |